Enlivex Therapeutics (Enlivex Therapeutics) Net Change in Cash : $-49.13 Mil (TTM As of Sep. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Enlivex Therapeutics Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Enlivex Therapeutics's Net Change in Cash for the three months ended in Sep. 2023 was $-1.49 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Sep. 2023 was $-49.13 Mil.

Enlivex Therapeutics Net Change in Cash Historical Data

The historical data trend for Enlivex Therapeutics's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enlivex Therapeutics Net Change in Cash Chart

Enlivex Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Change in Cash

Get a 7-Day Free Trial

-4.27

1.49

4.62

38.72

-49.13

Enlivex Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Net Change in Cash	Get a 7-Day Free Trial															-7.69	-36.81	-9.68	-1.49	-1.14

Enlivex Therapeutics Net Change in Cash Calculation

Enlivex Therapeutics's Net Change in Cash for the fiscal year that ended in Dec. 2022 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	-23.953	+	62.524	+	0.15	+	0
	=	38.72

Enlivex Therapeutics's Net Change in Cash for the quarter that ended in Sep. 2023

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= -5.439 + 3.945 + 0 + 0

= -1.49

Net Change in Cash for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-49.13 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enlivex Therapeutics Net Change in Cash Related Terms
Thank you for viewing the detailed overview of Enlivex Therapeutics's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Enlivex Therapeutics (Enlivex Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enlivex Therapeutics Ltd (NAS:ENLV) » Definitions » Net Change in Cash

Comparable Companies

RGLS CRBP VIRX CRIS ORGS CLRB AGE MRKR CLCS AURX OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX

Traded in Other Exchanges

ENLV:Israel 1BT:Germany

Address

14 Einstein Street, Nes Ziona, ISR, 7403618

Website

https://www.enlivex.com

Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.

Enlivex Therapeutics (Enlivex Therapeutics) Headlines

From GuruFocus

Enlivex Announces Reprioritization Plan and Second Quarter 2023 Financial Results
By Marketwired • 09-11-2023

Enlivex Announces Upcoming May Conference Presentations
By GuruFocusNews GuruFocusNews • 07-09-2022

Analysts At H.C. Wainwright & Co. Set 12-Month Target Of $15 Per Share For ENLV Thanks To High Profile Collaboration Agreement, Multiple Ongoing Clinical Trials
By ACCESSWIRE ACCESSWIRE • 04-14-2023

Enlivex Announces First Quarter 2023 Financial Results and Provides a Business Update
By Marketwired • 06-26-2023

Enlivex to Present at the H.C. Wainwright 25th Annual Global Investment Conference
By Marketwired • 09-07-2023

Enlivex Appoints Andrew Singer to its Board of Directors
By sperokesalga sperokesalga • 04-17-2023

Enlivex Presented Substantial Survival Benefit of Allocetra in Combination with Immune Checkpoint Inhibitor in Mesothelioma Cancer Study at the International Society for Cell and Gene Therapy Annual 2022 Meeting
By GuruFocusNews GuruFocusNews • 07-08-2022

Enlivex Announces Issuance of European Patent Covering the Use of Allocetra� to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell Therapy
By sperokesalga sperokesalga • 05-08-2023

Enlivex Announces Dosing of First Patient Under The Amended Protocol Of Its Phase II trial Evaluating Allocetra� In Patients With Sepsis
By Marketwired • 07-31-2023

Enlivex Receives Israeli Ministry of Health Approval for the Initiation of a Phase I/II Trial Evaluating Allocetra� Alone and in Combination with a PD1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors
By PurpleRose PurpleRose • 08-17-2022